CCL2 and metabolic dysfunction-associated steatohepatitis: On the other hand, pharmacological inhibition of CCL2 accelerated fibrosis resolution in mouse models of liver fibrosis [65], thereby supporting the development of drugs targeting CCL2 receptors for NASH therapy [66].